
"I am glad that taking part in a trial might help others on their own cancer journey.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at adding tiragolumab to atezolizumab and chemotherapy for small cell lung cancer.
It is for people:
You may have chemotherapy and atezolizumab as the first treatment for extensive small cell lung cancer. Researchers are trying to improve treatment. In this trial they are adding a drug called tiragolumab.
Tiragolumab is a new drug. It is type of immunotherapy. It blocks a protein in the body that stops the from working properly. Blocking this protein helps the immune system to find and fight cancer cells.
Atezolizumab is another type of immunotherapy drug. It works in a similar way to tiragolumab to stimulate the immune system. But it blocks a different protein.
The chemotherapy drugs you have in this trial are called carboplatin and etoposide. These are standard chemotherapy drugs used to treat small cell lung cancer.
In this trial some people have atezolizumab, chemotherapy and tiragolumab. And some people have atezolizumab, chemotherapy and a dummy drug ().
The main aims of the trial are to find out:
The following bullet points list the main entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply.
You:
Who can’t take part
You cannot join this trial if any of these apply.
Cancer related
You:
Medical conditions
You can’t take part if any of the following apply.
You:
Other
You can’t take part if any of the following apply.
You:
This is an international phase 3 trial. The researchers hope to find 470 people to take part including 13 people from the UK.
It is a randomised trial. There are 2 treatment groups. Neither you nor your doctor can decide which group you are in.
You have 1 of the following:
You have treatment in cycles. Each 3 week period is a.
Initial treatment (induction treatment)
For the first 4 cycles of treatment you have treatment as follows. On the first day of each cycle you have:
You have treatment once every 3 weeks. You also have etoposide on days 2 and 3 of each treatment cycle.
Cycle 1 to 4 |
Day 1 |
You have atezolizumab |
You have tiragolumab or the dummy drug |
You have carboplatin and etoposide |
Day 2 |
You have etoposide |
Day 3 |
You have etoposide |
Ongoing treatment (maintenance treatment)
From cycle 5 onwards you don’t have any more chemotherapy. You have treatment as follows. On the first day of each cycle you have:
You have treatment once every 3 weeks.
Cycle 5 onwards |
Day 1 |
You have atezolizumab |
You have tiragolumab or the dummy drug |
You have treatment for as long as it is working and the side effects aren’t too bad.
Quality of life
The trial team ask you to fill out a questionnaire before you start treatment and at set times during treatment. The questionnaire asks about side effects and how you’ve been feeling. This is called a quality of life study.
Blood and tissue samples
The researchers ask you to give 2 extra tissue samples. They also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
The researchers use the samples to look for differences in substances called . This can help researches work out why treatment might work for some people and not for others.
You don’t have to give these samples if you don’t want to. You can still take part in the trial.
You see a doctor and have some tests before you can join the trial. These include:
You have treatment at the hospital in the outpatient department. Each treatment visit takes between 4 and 6 hours. This might be slightly longer for the first cycle of treatment. You may also have some overnight stays. The team tell you when these happen.
You see the trial doctor once every 3 weeks for a check up and blood tests.
You have a CT scan, MRI scan or bone scan:
You see the team 1 month after you finish treatment. After that you see or speak with a member of the team every 3 months. This may be at a hospital visit or they may call you.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Tiragolumab and atezolizumab can affect the immune system. They may cause inflammation in different parts of the body which can cause serious side effects. They could happen during treatment, or some months after treatment has finished. Rarely, these side effects could be life threatening. If you have any of these side effects, you should tell the doctor or nurse as soon as possible. You should tell them that you are on or have been on an immunotherapy. |
Tiragolumab is a new drug so there may be side effects we don’t know about. The side effects we know about so far include:
You may have some medication before tiragolumab to reduce the risk of having a reaction to the infusion.
We have information about the side effects of:
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Raffaele Califano
Roche
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”